Cargando…

Abrogating endocrine resistance by targeting ERα and PI3K in breast cancer

Antiestrogen therapies targeting estrogen receptor α (ER) signaling are a mainstay for patients with ER+ breast cancer. While many cancers exhibit resistance to antiestrogen therapies, a large body of clinical and experimental evidence indicates that hyperactivation of the phosphatidylinositol 3-kin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fox, Emily M., Arteaga, Carlos L., Miller, Todd W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2012
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472546/ https://www.ncbi.nlm.nih.gov/pubmed/23087906 http://dx.doi.org/10.3389/fonc.2012.00145

Ejemplares similares

Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer
por: Liu, Shuying, et al.
Publicado: (2014)

Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation
por: Fox, Emily M, et al.
Publicado: (2013)

Re-Expression of ERα and AR in Receptor Negative Endocrine Cancers via GSK3 Inhibition
por: Sharma, Vikas, et al.
Publicado: (2022)

Hypoxia and ERα Transcriptional Crosstalk Is Associated with Endocrine Resistance in Breast Cancer
por: Jehanno, Charly, et al.
Publicado: (2022)

HOXA1 Is an Antagonist of ERα in Breast Cancer
por: Belpaire, Magali, et al.
Publicado: (2021)

miR-221/222 sponge abrogates tamoxifen resistance in ER-positive breast cancer cells through restoring the expression of ERα
por: Ouyang, Yan Xiu, et al.
Publicado: (2021)

FDXR drives primary and endocrine-resistant tumor cell growth in ER+ breast cancer via CPT1A-mediated fatty acid oxidation
por: Yan, Chaojun, et al.
Publicado: (2023)

Cryptotanshinone Inhibits ERα-Dependent and -Independent BCRP Oligomer Formation to Reverse Multidrug Resistance in Breast Cancer
por: Ni, Wenting, et al.
Publicado: (2021)

AKTIP loss is enriched in ERα-positive breast cancer for tumorigenesis and confers endocrine resistance
por: Ng, Angel S.N., et al.
Publicado: (2022)

Regulation of ERα Stability and Estrogen Signaling in Breast Cancer by HOIL-1
por: Ding, Jianing, et al.
Publicado: (2021)

Cystatin SN Affects Cell Proliferation by Regulating the ERα/PI3K/AKT/ERα Loopback Pathway in Breast Cancer
por: Liu, Yanfang, et al.
Publicado: (2019)

Rapamycin Antagonizes BCRP-Mediated Drug Resistance Through the PI3K/Akt/mTOR Signaling Pathway in mPRα-Positive Breast Cancer
por: Zhang, Jing, et al.
Publicado: (2021)

FOXM1 is a transcriptional target of ERα and has a critical role in breast cancer endocrine sensitivity and resistance
por: Millour, Julie, et al.
Publicado: (2010)

FOXM1 is a transcriptional target of ERα and has a critical role in breast cancer endocrine sensitivity and resistance
por: Millour, J, et al.
Publicado: (2010)

Unfolding the Role of Stress Response Signaling in Endocrine Resistant Breast Cancers
por: Clarke, Robert, et al.
Publicado: (2015)

Aurora-A Mitotic Kinase Induces Endocrine Resistance through Down-Regulation of ERα Expression in Initially ERα+ Breast Cancer Cells
por: Opyrchal, Mateusz, et al.
Publicado: (2014)

Abrogating Metastatic Properties of Triple-Negative Breast Cancer Cells by EGFR and PI3K Dual Inhibitors
por: Garcia, Ana Rita, et al.
Publicado: (2023)

ECM1 is associated with endocrine resistance in ER(+) breast cancers
por: Lee, Tae Won, et al.
Publicado: (2022)

Andrographolide Inhibits ER-Positive Breast Cancer Growth and Enhances Fulvestrant Efficacy via ROS-FOXM1-ER-α Axis
por: Xu, Tong, et al.
Publicado: (2022)

ERα-LBD, an isoform of estrogen receptor alpha, promotes breast cancer proliferation and endocrine resistance
por: Strillacci, Antonio, et al.
Publicado: (2022)

Targeting PI3K in Cancer: Any Good News?
por: Martini, Miriam, et al.
Publicado: (2013)

Targeting PI3K/mTOR Signaling in Cancer
por: Arcaro, Alexandre
Publicado: (2014)

miR-452 Reverses Abnormal Glycosylation Modification of ERα and Estrogen Resistance in TNBC (Triple-Negative Breast Cancer) Through Targeting UGT1A1
por: Li, Yan, et al.
Publicado: (2020)

Targeting WEE1 Inhibits Growth of Breast Cancer Cells That Are Resistant to Endocrine Therapy and CDK4/6 Inhibitors
por: Fallah, Yassi, et al.
Publicado: (2021)

Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER‐positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor
por: Karimi, Leena, et al.
Publicado: (2023)

Targeting MDK Abrogates IFN-γ-Elicited Metastasis inCancers of Various Origins
por: Zheng, Luyu, et al.
Publicado: (2022)

Metabolic Imaging Detects Resistance to PI3Kα Inhibition Mediated by Persistent FOXM1 Expression in ER(+) Breast Cancer
por: Ros, Susana, et al.
Publicado: (2020)

SAT-119 Targeting Glutamate Metabolism and Signaling in ER+, Endocrine Therapy-Resistant Breast Cancer
por: Olukoya, Ayodeji O, et al.
Publicado: (2020)

Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets
por: Saada-Bouzid, Esma, et al.
Publicado: (2019)

Targeting PI3K/Akt/mTOR Signaling in Cancer
por: Porta, Camillo, et al.
Publicado: (2014)

Heterogeneity of Phosphatidylinositol-3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin Activation in Cancer: Is PI3K Isoform Specificity Important?
por: Cintas, Célia, et al.
Publicado: (2018)

Nuclear Mechanisms Involved in Endocrine Resistance
por: Dittmer, Jürgen
Publicado: (2021)

Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
por: Liu, Shuying, et al.
Publicado: (2023)

Network-informed discovery of multidrug combinations for ERα+/HER2-/PI3Kα-mutant breast cancer
por: Hany, Dina, et al.
Publicado: (2023)

ERα/PR crosstalk is altered in the context of the ERα Y537S mutation and contributes to endocrine therapy-resistant tumor proliferation
por: Huggins, Rosemary J., et al.
Publicado: (2023)

Targeting the PI3K/mTOR Pathway in Pediatric Hematologic Malignancies
por: Tasian, Sarah K., et al.
Publicado: (2014)

Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment
por: Liu, Shuying, et al.
Publicado: (2023)

MicroRNA-326 Functions as a Tumor Suppressor in Breast Cancer by Targeting ErbB/PI3K Signaling Pathway
por: Ghaemi, Zahra, et al.
Publicado: (2019)

microRNA-Dependent Modulation of Genes Contributes to ESR1's Effect on ERα Positive Breast Cancer
por: Gao, Shan, et al.
Publicado: (2020)

CD147: an integral and potential molecule to abrogate hallmarks of cancer
por: Nyalali, Alphonce M. K., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_envouhrdgeh0m9qu714c3repdj